Condition

HER2+ Breast Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 10 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials10
Recruiting3
Common interventions23
Lead sponsors shown10
Advertisement

Clinical trials

10 shown
Breast Cancer Evolution During Neoadjuvant Systemic TherapyNCT06681064 · 2024-05-29
RECRUITING
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast CancerNCT05534438 · 2022-09-06
RECRUITING
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750 · 2020-10-29
RECRUITING
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed TherapyNCT06844669 · 2025-04-16
TERMINATED
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast CancerNCT06537674 · 2024-08-15
NOT_YET_RECRUITING
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic ReviewNCT05931042 · 2023-06-01
COMPLETED
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)NCT04296942 · 2021-05-04
TERMINATED
Precise Therapy for Refractory HER2 Positive Advanced Breast CancerNCT05429684 · 2021-01-01
UNKNOWN
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast CancerNCT03632941 · 2019-03-01
TERMINATED
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast CancerNCT01132664 · 2010-05-01
TERMINATED

Common interventions

TrastuzumabDRUG3CapecitabineDRUG2Ado-trastuzumab emtansineBIOLOGICAL1AIDRUG1Anti-PD-1 monoclonal antibodyDRUG1BKM120DRUG1Brachyury-TRICOMBIOLOGICAL1CarvedilolDRUG1CDK4/6 inhibitorDRUG1EmpagliflozinDRUG1EntinostatDRUG1EverolimusDRUG1M7824BIOLOGICAL1Nab paclitaxelDRUG1PembrolizumabBIOLOGICAL1pembrolizumabDRUG1PertuzumabDRUG1PyrotinibDRUG1rezatapoptDRUG1Stereotactic body radiotherapyRADIATION1T-DM1DRUG1Trastuzumab intravenous drip/Trastuzumab Subcutaneous InjectionDRUG1VRP-HER2BIOLOGICAL1

Trial status mix

TERMINATED4
RECRUITING3
COMPLETED1
NOT_YET_RECRUITING1
UNKNOWN1

Phase mix

PHASE25
PHASE13
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.